Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy

Dieuwertje E. Kok; Maaike M. G. A. van den Berg; Liesbeth Posthuma; Iris van ’t Erve; Fränzel J. B. van Duijnhoven; Wilfred K. de Roos; Sissi Grosfeld; Maartje Los; Dirkje W. Sommeijer; Hanneke W. M. van Laarhoven; Renate M. Winkels; Ellen Kampman

doi:10.1080/01635581.2018.1559938

Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy

Dieuwertje E. Kok, Maaike M. G. A. van den Berg, Liesbeth Posthuma, Iris van ’t Erve, Fränzel J. B. van Duijnhoven, Wilfred K. de Roos, Sissi Grosfeld, Maartje Los, Dirkje W. Sommeijer, Hanneke W. M. van Laarhoven, Renate M. Winkels, Ellen Kampman

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D 3 ) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D 3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D 3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D 3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D 3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D 3 levels after chemotherapy. We reported lower 25(OH)D 3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D 3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.

Original language	English
Pages (from-to)	756-766
Journal	Nutrition and Cancer
Volume	71
Issue number	5
DOIs	https://doi.org/10.1080/01635581.2018.1559938
Publication status	Published - 4 Jul 2019
Externally published	Yes

Access to Document

10.1080/01635581.2018.1559938

Cite this

Kok, D. E., van den Berg, M. M. G. A., Posthuma, L., van ’t Erve, I., van Duijnhoven, F. J. B., de Roos, W. K., Grosfeld, S., Los, M., Sommeijer, D. W., van Laarhoven, H. W. M., Winkels, R. M., & Kampman, E. (2019). Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy. Nutrition and Cancer, 71(5), 756-766. https://doi.org/10.1080/01635581.2018.1559938

@article{74d245e93c6a475682f628b4204944f1,

title = "Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy",

abstract = "Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D 3 ) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D 3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D 3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D 3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D 3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D 3 levels after chemotherapy. We reported lower 25(OH)D 3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D 3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.",

author = "Kok, {Dieuwertje E.} and {van den Berg}, {Maaike M. G. A.} and Liesbeth Posthuma and {van {\textquoteright}t Erve}, Iris and {van Duijnhoven}, {Fr{\"a}nzel J. B.} and {de Roos}, {Wilfred K.} and Sissi Grosfeld and Maartje Los and Sommeijer, {Dirkje W.} and {van Laarhoven}, {Hanneke W. M.} and Winkels, {Renate M.} and Ellen Kampman",

year = "2019",

month = jul,

day = "4",

doi = "10.1080/01635581.2018.1559938",

language = "English",

volume = "71",

pages = "756--766",

journal = "Nutrition and Cancer",

issn = "0163-5581",

publisher = "Routledge",

number = "5",

}

Kok, DE, van den Berg, MMGA, Posthuma, L, van ’t Erve, I, van Duijnhoven, FJB, de Roos, WK, Grosfeld, S, Los, M, Sommeijer, DW , van Laarhoven, HWM, Winkels, RM & Kampman, E 2019, 'Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy', Nutrition and Cancer, vol. 71, no. 5, pp. 756-766. https://doi.org/10.1080/01635581.2018.1559938

TY - JOUR

T1 - Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy

AU - Kok, Dieuwertje E.

AU - van den Berg, Maaike M. G. A.

AU - Posthuma, Liesbeth

AU - van ’t Erve, Iris

AU - van Duijnhoven, Fränzel J. B.

AU - de Roos, Wilfred K.

AU - Grosfeld, Sissi

AU - Los, Maartje

AU - Sommeijer, Dirkje W.

AU - van Laarhoven, Hanneke W. M.

AU - Winkels, Renate M.

AU - Kampman, Ellen

PY - 2019/7/4

Y1 - 2019/7/4

N2 - Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D 3 ) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D 3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D 3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D 3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D 3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D 3 levels after chemotherapy. We reported lower 25(OH)D 3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D 3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.

AB - Cancer treatments, toxicities and their effects on lifestyle, may impact levels of vitamin D. The aim of this study was to determine serum 25-hydroxyvitamin D3 (25(OH)D 3 ) levels before, directly after and 6 months after chemotherapy in breast cancer patients (n = 95), and a comparison group of women (n = 52) not diagnosed with cancer. Changes in 25(OH)D 3 levels over time were compared using linear mixed models adjusted for age and season of blood sampling. Before start of chemotherapy, 25(OH)D 3 levels were lower in patients (estimated marginal mean 55.8 nmol/L, 95% confidence interval (95%CI) 51.2–60.4) compared to the comparison group (67.2 nmol/L, 95%CI 61.1–73.3, P = 0.003). Directly after chemotherapy, 25(OH)D 3 levels were slightly decreased (–5.1 nmol/L, 95%CI –10.7–0.5, P = 0.082), but ended up higher 6 months after chemotherapy (10.9 nmol/L, 95%CI 5.5–16.4, P < 0.001) compared to pre-chemotherapy values. In women without cancer, 25(OH)D 3 levels remained stable throughout the study. Use of dietary supplements did not explain recovery of 25(OH)D 3 levels after chemotherapy. We reported lower 25(OH)D 3 levels in breast cancer patients, which decreased during chemotherapy, but recovered to levels observed in women without cancer within 6 months after chemotherapy. Suboptimal 25(OH)D 3 levels in the majority of the participants highlight the relevance of monitoring in this vulnerable population.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060334832&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30661404

U2 - 10.1080/01635581.2018.1559938

DO - 10.1080/01635581.2018.1559938

M3 - Article

C2 - 30661404

VL - 71

SP - 756

EP - 766

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 5

ER -

Changes in Circulating Levels of 25-hydroxyvitamin D3 in Breast Cancer Patients Receiving Chemotherapy

Abstract

Access to Document

Other files and links

Cite this